View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
Sponsored by Emisphere Technologies

Study: Pharmacokinetics of Oral Cyanocobalamin Formulated with SNAC

Free White Paper

Study: Pharmacokinetics of Oral Cyanocobalamin Formulated with SNAC

By Emisphere Technologies

Study: Pharmacokinetics of Oral Cyanocobalamin Formulated with SNAC

By Emisphere Technologies
Enter your details to receive the free paper:

Originally published by Elsevier Journals on 24 May 2011, this white paper outlines an open-label, randomised, single-dose, parallel-group study of the pharmacokinetics of oral cyanocobalamin formulated with Sodium N-[8-(2-hydroxy benzoyl) amino] caprylate (SNAC).

Vitamin B12 deficiency may be caused by inadequate dietary intake or by conditions that result in malabsorption. Usually in the form of cyanocobalamin, crystalline vitamin B12 is administered parenterally or orally for the treatment of deficiency states.

Intramuscular administration is widely accepted as a treatment method and oral B12 supplements are also used but are considered less reliable.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena